Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
May 10, 2022
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
May 3, 2022
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
April 21, 2022
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
March 28, 2022
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
March 21, 2022
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
March 8, 2022
Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA
March 2, 2022
Revance to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022
Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update
February 22, 2022
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
January 18, 2022
Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA
Displaying 1 - 10 of 277